Heterocyclic Compounds

Matches 1 - 50 out of 36,928	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >

Document	Document Title
WO/2024/097629A1	BRIDGED BICYCLIC HETEROCYCLOALKYL PYRIDO-[3,4-D]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORS The present disclosure relates to compounds of Formula (I): or pharmaceutically acceptable salts or isotopically labeled derivatives thereof, wherein A is a 6- to 10- membered bridged bicyclic heterocycloalkyl comprising at least one oxy...
WO/2024/098001A1	NAPHTHYRIDONE COMPOUNDS FOR INHIBITION OF RAF KINASES The present disclosure relates to compounds (I) and compositions for inhibition of RAF serine/threonine protein kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as mel...
WO/2024/097296A1	ANTI-VIRAL COMPOUNDS Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
WO/2024/097953A1	NAPHTHYRIDINE COMPOUNDS FOR INHIBITION OF RAF KINASES The present disclosure relates to compounds (I) and compositions for inhibition of RAF serine/threonine protein kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers.
WO/2024/094163A1	POLYCYCLIC RING-FUSED DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF Disclosed are a polycyclic ring-fused derivative, a preparation method therefor, and use thereof. In particular, disclosed are a compound represented by general formula (I-2-1), a preparation method therefor, a pharmaceutical composition...
WO/2024/097575A1	PREPARATION OF TRIAZOLOPYRIDINE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS Provided are compounds of formula I and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising c...
WO/2024/094185A1	NLRP3 INFLAMMASOME INHIBITOR AND USE THEREOF The present invention belongs to the technical field of medicine, relates to an NLRP3 inflammasome inhibitor and a use thereof, and specifically relates to a compound represented by a general formula (A') or a pharmaceutically acceptable...
WO/2024/093956A1	POLYCYCLIC POLY(ADP-RIBOSE) POLYMERASE SELECTIVE INHIBITOR The present invention relates to the technical field of medicines, in particular to a polycyclic poly(ADP-ribose) polymerase (PARP) selective inhibitor compound as represented by general formula (I), a pharmaceutically acceptable salt th...
WO/2024/097573A1	PREPARATION OF IMIDAZOPYRIDINE AND IMIDAZOPYRIDAZINE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS Provided are compounds of formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising...
WO/2024/096093A1	HETEROCYCLIC COMPOUND AND HARMFUL ARTHROPOD CONTROL COMPOSITION CONTAINING SAME The present invention provides a compound that has excellent control effects on harmful arthropods. Compounds represented by formula (I) (the meanings of the symbols of which are described in the description) or N-oxides thereof have exc...
WO/2024/097172A1	ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3‑kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): (I) or pharmaceut...
WO/2024/095133A1	HETEROCYCLIC COMPOUND The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful a...
WO/2024/095012A1	PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS The invention relates to a compound of formula (Ia) and related aspects.
WO/2024/097897A1	LXR MODULATORS WITH BICYCLIC CORE MOIETY FOR TREATING DYSLIPIDEMIAS The present disclosure relates to novel compounds which are Liver X Receptor (LXR) modulators and to pharmaceutical compositions containing same. The present disclosure further relates to the use of said compounds in the prophylaxis and/...
WO/2024/094190A1	IRAK4 DEGRADATION AGENT AND USE THEREOF The present invention relates to use of compounds of formula I and formula II, and specifically relates to use of compound A1-A52, B1-B5, or C1-C36 in the preparation of a drug for treating and/or preventing an inflammatory or immune dis...
WO/2024/097606A1	AHR AGONISTS The present disclosure relates to certain AHR agonist compounds, for example, having a general formula (I) to pharmaceutical compositions comprising the compounds, and to methods of using the compounds to treat immune-mediated diseases, ...
WO/2024/094963A1	2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER Provided are 2-amino-pyrido[2,3-d]pyrimidin-7(8H)-one and 7- amino-l-pyrimido[4,5-d]pyrimidin-2(lH)-one derivatives of the Formula (I), and salts, hydrates and solvates thereof. The compounds are inhibitors of EGFR, including mutated for...
WO/2024/095172A1	PRODRUGS OF VARENICLINE AND COMPOUNDS CONTAINING VULNERABLE AMINES The present invention relates to prodrugs of compounds that contain vulnerable amines (e,g, secondary, tertiary and quaternary amines), and methods for their manufacture.
WO/2024/094181A1	METHOD FOR PREPARING FINERENONE BY MEANS OF RESOLVING RACEMATE WITH DIASTEREOMERIC TARTARIC ESTER The present invention provides a method for preparing finerenone by means of resolving a racemate with a diastereomeric tartaric ester, and also relates to diastereomer salts (VIIa), (VIIb), (VIIc) and/or (VIId). The resolving method use...
WO/2024/095179A1	LIPID COMPOUNDS AND USES THEREOF Compounds are provided having the following structure: (I) or a pharmaceutically acceptable salt, N-oxide, tautomer or stereoisomer thereof, wherein R1, G1, W and m, n, o and p are as defined herein. Use of the compounds as a component o...
WO/2024/094962A1	PYRIDO[2,3-D]PYRIMIDIN-2-AMINE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER Provided are pyrido[2,3-d]pyrimidin-2-amine derivatives of the Formula (I), and salts, hydrates and solvates thereof. The compounds are inhibitors of EGFR, including mutated forms of EGFR (for example EGFR comprising a T790M mutation, a ...
WO/2024/094875A1	CHROMEN-4-ONE COMPOUNDS WITH ANTICANCER PROPERTIES The present invention relates to compounds, and to associated salts, solvates and pharmaceutical compositions. The present invention also relates to the use of such compounds and compositions in the treatment and prevention of medical di...
WO/2024/097576A1	PREPARATION OF PYRAZOLOPYRIDINE AND TRIAZOLOPYRIDINE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS Provided are compounds of Formula I, Formula Ib or Formula Ic and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, Formula Ib or ...
WO/2024/088379A1	TUMOR TREATMENT OR PREVENTION METHOD Disclosed is a tumor treatment or prevention method. The method comprises: administering, to an individual in need of the method, a therapeutically or prophylactically effective amount of a compound represented by general formula (I), or...
WO/2024/088237A1	LUMINESCENT MATERIAL, USE THEREOF, AND ORGANIC ELECTROLUMINESCENT DEVICE CONTAINING SAME Compounds of a general formula, the use thereof, and an organic electroluminescent device containing same. The compounds have structures represented by formula (1), wherein the dotted line represents ring A being an optional structure; w...
WO/2024/089008A1	HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING The present invention relates to compounds of formula (I) which are capable of activating STING (Stimulator of Interferon Genes). The present invention further relates to pharmaceutical compositions comprising at least a compound of form...
WO/2024/088922A1	HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, L, W, Y, Z, and R1 to R3 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods o...
WO/2024/088069A1	PREPARATION FOR AROMATIC KRAS MUTANT PROTEIN INHIBITOR AND USE THEREOF Compounds of general formula (I) and formula (II) have good activity for inhibiting tumor growth and have good safety. Provided are preparation for a Kras inhibitor and a use thereof. Specifically, provided are compounds represented by f...
WO/2024/092037A1	SPIROCYCLE CONTAINING PYRIDONE COMPOUNDS Provided herein are compounds that stabilize immunoglobulin light chains, and pharmaceutically acceptable derivatives thereof. Also provided are pharmaceutical compositions containing the compounds and methods of using the compounds for ...
WO/2024/089702A1	AN IMPROVED PROCESS FOR THE PREPARATION OF TUCATINIB AND ITS SALT & POLYMORPHS THEREOF The present invention relates to an improved process for the preparation of (N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylpheny l)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-d iamine compound of formula-1 and its sa...
WO/2024/090919A1	IMPROVED PROCESSES FOR PREPARING DIMETHYL-2,3-DIHYDRO-1H-INDENE DERIVATIVES The present invention provides an improved process for preparing a dimethyl-2,3-dihydro-1H-indene derivative or a pharmaceutically acceptable salt thereof. And, the present invention provides novel intermediates useful for the process. W...
WO/2024/092069A1	CXCR4 INHIBITORS FOR TREATMENT OF NEUROLOGICAL DISEASES The present invention provides CXCR4 inhibitors of Formula (I): and pharmaceutically acceptable salts thereof, and methods for their use in treating neurological and CNS diseases, disorders, and conditions.
WO/2024/092043A1	SPIROCYCLE CONTAINING PYRIDINE COMPOUNDS Provided herein are compounds that stabilize immunoglobulin light chains, and pharmaceutically acceptable derivatives thereof. Also provided are pharmaceutical compositions containing the compounds and methods of using the compounds for ...
WO/2024/064214A3	SYNTHESIS OF CYCLOPROPANE CARBOXYLIC ACIDS The present disclosure provides methods of preparing substituted cyclopropane compounds.
WO/2024/091450A1	COMPOUNDS AND METHODS FOR TREATING CANCER The present disclosure relates to compounds for treating cancer. The compounds may prevent conversion of non-stem cancer cells into cancer-initiating cells caused by radiation treatment.
WO/2024/088408A1	NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF Disclosed are a nitrogen-containing heterocyclic compound, a pharmaceutically acceptable salt thereof, a preparation method therefor and the use thereof. Provided is a compound as shown in formula (I) or a pharmaceutically acceptable sal...
WO/2024/092222A1	MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR D AND RELATED PRODUCTS AND METHODS Methods are provided for modulating MRGPRD generally, or for treating a MRGPRD dependent condition more specifically, by contacting the MRGPRD or administering to a subject in need thereof, respectively, an effective amount of a compound...
WO/2024/090917A1	NOVEL SALT OF DIMETHYL-2,3-DIHYDRO-1H-INDENE DERIVATIVE AND PROCESSES FOR PREPARING THE SAME The present invention provides a novel salt of (S)-quinuclidin-3-yl ((R)-5-(3-chloro-4-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydr o-1H-inden-1-yl)carbamate, i.e., (1S)-(+)-10-camphorsulfonic acid salt thereof and a process for preparing t...
WO/2024/088285A1	MESYLATE OF HETEROCYCLIC SUBSTITUTED FUSED γ-CARBOLINE DERIVATIVE, CRYSTAL FORM AND PREPARATION METHOD THEREFOR AND USE THEREOF The present invention relates to a mesylate of a heterocyclic substituted fused γ-carboline derivative, a crystal form and a preparation method therefor and a use thereof. In particular, the present invention relates to a mesylate of co...
WO/2024/088351A1	COMPOUNDS AND USES THEREOF Disclosed herein are compounds or pharmaceutically acceptable salts thereof that are useful as inhibitors for activity of a BAF complex. Also disclosed are pharmaceutical compositions comprising such compounds, and methods of using such ...
WO/2024/088307A1	NOVEL PEPTIDYL NITRILE COMPOUND AND USE THEREOF Disclosed are a novel peptidyl nitrile compound and a use thereof, and specifically disclosed are a compound of formula (I) and/or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound and/or th...
WO/2024/064701A3	ADENOSINE ANALOGS FOR THE TREATMENT OF DISEASE The disclosure provides adenosine analogs for the treatment of disease such as pain and inflammatory conditions.
WO/2024/090469A1	FUSED PYRIDAZINE DERIVATIVE The present invention addresses the problem of providing a pharmaceutical composition, particularly a compound that is suitable for preventing and/or treating inflammatory diseases and/or neurodegenerative diseases.　The inventors of th...
WO/2024/091538A1	COMPOUNDS AND COMPOSITIONS AS GPR52 MODULATORS The present disclosure relates to compounds of Formula (I) capable of modulating the activity of GPR52. The present disclosure further provides a process for the preparation of compounds of Formula (1) and methods of using compounds of F...
WO/2024/089155A1	HETEROCYCLIC COMPOUNDS AS STING ANTAGONISTS This invention relates to compounds of formula (1), and their use as STING antagonists e.g. for the treatment of a disease selected from the group consisting of systemic lupus erythematosus (SLE), (monogenic and digenic) interferonopathi...
WO/2024/091541A1	COMPOUNDS AND COMPOSITIONS AS GPR52 MODULATORS The present disclosure relates to compounds of Formula (I) capable of modulating the activity of GPR52. The present disclosure further provides a process for the preparation of compounds of Formula (1) and methods of using compounds of F...
WO/2024/089006A1	HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING The present invention relates to compounds of formula (I) which are capable of activating STING (Stimulator of Interferon Genes). The present invention further relates to pharmaceutical compositions comprising at least a compound of form...
WO/2024/088296A1	PIPERIDINOPYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE The present disclosure relates to a piperidinopyrimidine derivative, a preparation method therefor and the use thereof in medicine. Specifically, the present disclosure relates to a piperidinopyrimidine derivative as represented by gener...
WO/2024/088402A1	CRYSTAL FORM OF ISOQUINOLINONE COMPOUND AND PREPARATION METHOD THEREFOR The present disclosure relates to a crystal form of an isoquinolinone compound and a preparation method therefor. Specifically, provided in the present disclosure are a crystal form of a compound as represented by formula (I) and a prepa...
WO/2024/086790A1	4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-c]PYRIDINE COMPOUNDS AND DERIVATIVES AS USP1 INHIBITORS The present disclosure provides 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine compounds of formula (I), which are therapeutically useful as USP1 inhibitors. These compounds are useful in the treatment and/or prevention of diseases and/or...

Matches 1 - 50 out of 36,928	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >